The UK's GSK - GLAXOSMITHKLINE is bidding 1.7 Canadian dollars for Canada's ID BIOMEDICAL (2004 turnover 53.66 mil dollar, workforce of 500) to boost its flu vaccine production capacity. ID BIOMEDICAL's shareholders will get 35 Canadian dollars for each share. The deal will enable GSK to produce 75 million 'Fluviral' doses a year. Other changes in pharmaceuticals: last week, Swiss company NOVARTIS bid USD 4.5 bn for the 58% share of the US's CHIRON it does not already own.